Slide 1: Q4 Earnings Supplemental Materials
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Q4 Earnings Supplemental Materials March 8, 2023 1
Slide 2: Disclaimer
Advancing medicines. Solving problems. Improving lives. ® Disclaimer This presentation contains “forward-looking” statements that are based on the beliefs and assumptions and on information currently available to management of Aquestive Therapeutics, Inc. (together with its consolidated subsidiary,
Slide 3: Q4 2022 Earnings: Key Messages
Advancing medicines. Solving problems. Improving lives. Q4 2022 Earnings: Key Messages AQST-109 (Epinephrine Sublingual Film) Completed End-of-Phase 2 (EoP2) meeting with the FDA in December 2022 On track to start pivotal pharmacokinetic (PK) study in Q3 2023 with top-line data readout anticipat
Slide 4: Strong Ending to 2022
Advancing medicines. Solving problems. Improving lives. 4 Strong Ending to 2022…. - Positive decision to dismiss Aquestive from Suboxone® States’ antitrust case - Sympazan® licensing deal with Otter Pharmaceuticals, subsidiary of Assertio Holdings NOVEMBER - Completion of End-of-Phase 2 meeting with
Slide 5: Cash Position Strengthened Each Quarter in 2022
Advancing medicines. Solving problems. Improving lives. 5 Cash Position Strengthened Each Quarter in 2022 14.7 17.7 18.6 27.3 0 5 10 15 20 25 30 Ending Cash Ending Cash by Quarter Q1 2022 Q2 2022 Q3 2022 Q4 2022 All figures in USD millions
Slide 6: Debt Position Forecasted to Decrease in Q1 and Throughout 2023
Advancing medicines. Solving problems. Improving lives. 6 Debt Position Forecasted to Decrease in Q1 and Throughout 2023 51.5 42.4 39.0 34.4 29.8 0 10 20 30 40 50 60 Ending Cash Forecasted Debt by Quarter Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 All figures in USD millions
Slide 7: Limited Common Share Issuance Since June 2022 Capital Raise
Advancing medicines. Solving problems. Improving lives. 7 Limited Common Share Issuance Since June 2022 Capital Raise 45,462,516 53,424,922 54,390,696 Q2 2022 Q3 2022 Q4 2022 Weighted Average Common Shares Outstanding by Quarter
Slide 8: Manufacturing Operations
Advancing medicines. Solving problems. Improving lives. Manufacturing Operations 8
Slide 9: Manufacturing Operations Continues to Meet Expectations and Generate Cash Flow
Advancing medicines. Solving problems. Improving lives. Manufacturing Operations Continues to Meet Expectations and Generate Cash Flow 9 27,890 30,916 49,182 47,505 36,413 42,182 47,041 41,097 36,863 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 PHARMFILM® VOLUME (MILLIONS)
Slide 10: 2023 Outlook
Advancing medicines. Solving problems. Improving lives. 2023 Outlook 10
Slide 11: 2023 Outlook Update
Advancing medicines. Solving problems. Improving lives. 2023 Outlook Update 2023 Outlook • Total revenues of approximately $37 to $41 million • Non-GAAP adjusted EBITDA loss of approximately $31 to $36 million 11
Slide 12: Thank You
Advancing medicines. Solving problems. Improving lives. Thank You